Sunshine Biopharma director Andrew Keller to leave board at next annual meeting
Dr. Andrew Keller informed Sunshine Biopharma on August 25, 2026 that he does not plan to stand for another term on its board.
SEC filing
Latest
5 stories
Friday, August 28
Sunshine Biopharma files S-1 for shares tied to Series B warrants
The company registered 25,477,133 shares underlying warrants issued in a February 2024 offering to require cash exercise going forward.
SEC filing
Monday, July 20
Sunshine Biopharma files $4 million at-the-market stock offering with Aegis Capital
The prospectus supplement, dated July 20, 2026, lets Sunshine Biopharma sell shares through Aegis as sales agent for general corporate purposes.
SEC filing
Sunshine Biopharma sets up $4 million at-the-market stock sale facility with Aegis Capital
The company can sell up to $4,000,000 of common stock over time through Aegis Capital under a new sales agreement dated July 20, 2026.
SEC filing
Friday, July 10
Sunshine Biopharma settles dispute with former Nora Pharma president
The company will pay Malek Chamoun about CAD$1.5 million to resolve a disagreement tied to his former role at its Nora Pharma subsidiary.
SEC filing